Recent Price Moves and Long Term Context

Intellia Therapeutics (NTLA) has drawn attention after recent price moves, with the stock last closing at US$14.16. Short term returns have been mixed, while longer horizons show very different outcomes.

The recent pullback, with a 1 day share price return of negative 5.22%, comes after a stronger run that includes a 53.75% year to date share price return and a 95.85% 1 year total shareholder return. However, longer term total shareholder returns remain negative.

If you are comparing Intellia with other gene editing and biotech names, it can be helpful to widen the lens to related healthcare AI opportunities by scanning 35 healthcare AI stocks

With Intellia trading at US$14.16 against an analyst price target of about US$25 and an intrinsic value implying an even larger gap, is the market overlooking potential or already pricing in the next phase of growth?

Most Popular Narrative: 44% Undervalued

With Intellia Therapeutics last closing at $14.16 and the most followed narrative pointing to a fair value of $25.29, the gap between price and modelled value is wide enough that the underlying assumptions matter a lot.

The sustained expansion of the addressable market for Intellia's programs is reinforced by demographic trends, especially aging populations and the continued rise in genetic and chronic conditions like ATTR amyloidosis and HAE, supporting higher future patient volumes and underpinning potential multi-launch revenue inflection points.

Curious what has to happen for that valuation to stack up? The narrative leans on rapid revenue growth, rising margins and a premium earnings multiple. The exact mix of those inputs is where the story gets interesting.

Result: Fair Value of $25.29 (UNDERVALUED)

However, this narrative can crack if key Phase 3 trials disappoint on safety or efficacy, or if payer pushback on high one time gene editing costs limits adoption.

Another Way to Look at Value

While the narrative points to a fair value of $25.29, Simply Wall St's DCF model goes much further and estimates the future cash flow value at $150.49, with the current $14.16 share price trading about 90.6% below that level. If both views use the same business, which one do you lean toward?

Next Steps

The mix of optimism and concern around Intellia is clear, so it makes sense to move quickly, review the full data, and weigh up 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Intellia has your attention, do not stop here. Use the tools available to quickly spot other opportunities and make sure you are not leaving ideas on the table.

• Target potential bargains by scanning companies that combine quality fundamentals with attractive pricing using the 58 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses that show robust finances through the solid balance sheet and fundamentals stocks screener (42 results).
• Hunt for lesser known opportunities before they are widely discussed by reviewing the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.